Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 8

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 8
---
 of which may be designated from time to time by ParentCo’s board of directors;

(3) Advisory Charter Proposal C — to provide that the removal of any director be only for cause and by the affirmative vote of at least 66 2 ∕ 3 % of ParentCo’s then-outstanding shares of capital stock entitled to vote generally in the election of directors;

(4) Advisory Charter Proposal D — to make ParentCo’s corporate existence perpetual as opposed to Iris’s corporate existence, which is required to be dissolved and liquidated 51 months following the closing of its initial public offering if it does not complete a business combination in that time, and to remove from the Proposed ParentCo Certificate of Incorporation the various provisions applicable only to special purpose acquisition corporations;

(5) Advisory Charter Proposal E — to provide that ParentCo will not be subject to Section 203 of the DGCL; and

(6) Advisory Charter Proposal F — to increase the required vote thresholds for approving amendments to the Proposed ParentCo Certificate of Incorporation and bylaws to 66 2 ∕ 3 %.

TABLE OF CONTENTS

The Business Combination is not conditioned on the separate approval of the Advisory Charter Proposals (separate and apart from approval of the Charter Proposal). (Proposal No. 5 ). The Advisory Charter Proposals are described in more detail in the accompanying proxy statement/ prospectus under the heading “ The Advisory Charter Proposals (Proposal No. 5). ”

(f)

The Election of Directors Proposal — If the Business Combination Proposal and ParentCo Charter Proposal are approved, to consider and vote, on an advisory and non-binding basis, upon a proposal to elect the following three directors to serve on the board of directors of the post-Business Combination Company: Nicholas Fernandez and Ji Yeon Baek, as Class I directors, until the 2026 annual meeting of stockholders, Eun Sook Lee, as a Class II director, until the 2027 annual meeting of stockholders and Chris Kim, as a Class III director, until the 2028 annual meeting of stockholders, and, in each case, until their respective successors are duly elected and qualified (Proposal No. 6); and

(g)

The Adjournment Proposal — to consider and vote upon a proposal to approve the adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and voting of proxies if, based upon the tabulated vote at the time of the Special Meeting, there are not sufficient votes